CDK5 inhibitor 20-223 |
Catalog No.GC60680 |
L'inhibiteur de CDK5 20-223 est un puissant inhibiteur de CDK2 et de CDK5 avec des IC50 de 6,0 et 8,8 nM, respectivement. L'inhibiteur de CDK5 20-223 est un agent efficace contre le cancer colorectal (CRC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 865317-30-2
Sample solution is provided at 25 µL, 10mM.
CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent[1].
CDK5 inhibitor 20-223 (10 nM-10 μM; 72 hours) potently inhibits cell growth in a panel of colorectal cancer (CRC) cell lines[1].CDK5 inhibitor 20-223 (0.3125-20 μM; 6 hours) induces a dose-dependent decrease in pRB (S807/811) and pFAK (S732) levels in each of the three CRC cell lines[1]. Cell Viability Assay[1] Cell Line: CRC cell lines SW620, DLD1, HT29, HCT116, FET, CBS, and GEO cells
CDK5 inhibitor 20-223 (8mg/kg; subcutaneously; for 14 injections) shows anti-tumor activity in human CRC xenograft tumors in nude mice[1]. Animal Model: Athymic nude mice[1]
[1]. Caroline M Robb, et al. Characterization of CDK(5) Inhibitor, 20-223 (Aka CP668863) for Colorectal Cancer Therapy. Oncotarget. 2017 Dec 28;9(4):5216-5232.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *